GILEAD SCIENCES, INC.

Reported 2026-08-04

IN-LINE

51EarnIQ signal

↗

Confidence rising

Mild quarter-over-quarter shift

Strong base business and HIV growth offset large acquisition-related IPR&D charges, prompting raised revenue guidance.

✓Guidance was raised, with high specificity.
✓Management tone registered as confident (85/100).
✓EarnIQ detected 0 potential management deflections.

Headline–confidence gap

Mixed evidence

The headline and management signals do not point in one direction (confidence rising).

EPS: reported vs expected+8.5%$-6.75 vs $-7.38

Revenue: reported vs expected+3.4%$7.8B vs $7.5B

Guidance specificityHighRaised

Market expectations supplied by Finnhub · Reported vs consensus estimate

Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi.

✦

EarnIQ Premium

Understand exactly why confidence changed.

Unlock management-language evidence, guidance specificity, the pressure point, narrative breaks, risks, and quarter-over-quarter topic changes.

Guidance specificityPressure pointNarrative breakSource evidence

Preview full report